Versameb AG Email Format
Biotechnology ResearchBasel-stadt, Switzerland2-10 Employees
Versameb AG is a privately held biotechnology company based in Basel, in the Basel-Stadt region of Switzerland. It focuses on discovering and developing RNA-based therapeutics to modulate protein expression. The organization aims to influence multiple therapeutic targets with a single molecular construct and targeted cellular delivery. Its proprietary platform, VERSagile, is designed to broaden the druggable potential of RNA across different disease contexts. The company has been fully operational since 2018 and is based in Basel as a small biotechnology firm focused on advancing RNA therapeutics toward clinical development. In November 2023, the FDA cleared an IND for VMB-100 to treat Stress Urinary Incontinence, marking a notable regulatory development.